wanxun norvancomycin hydrochloride injection 0

Description

Indication & Scope

WanXun® is a prescription glycopeptide antibiotic indicated for the treatment of severe infections caused by susceptible Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), and other multidrug-resistant Gram-positive pathogens.

Mechanism: Norvancomycin binds to the D-alanyl-D-alanine terminus of bacterial cell wall precursors, blocking peptidoglycan synthesis and causing bacterial cell death.
Drug class: Glycopeptide antibacterial agent.
Clinical use: Treatment of severe MRSA/MRSE infections, including pneumonia, bacteremia, endocarditis, osteomyelitis, severe skin and soft tissue infections, and oral treatment of Clostridioides difficile–associated colitis.

Specification

Generic Name	Norvancomycin Hydrochloride for Injection
Brand Name	WanXun®
Ingredient	Norvancomycin hydrochloride
Dosage Form	Injection
Package	0.4 g/vial, 1 vial/carton
Conditions Treated	MRSA/MRSE infections, severe Gram-positive bacterial infections, pneumonia, bacteremia, endocarditis, osteomyelitis, skin and soft tissue infections, C. difficile infection
Taboos	Hypersensitivity to norvancomycin, vancomycin, teicoplanin, or other glycopeptide antibiotics
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 25°C in a dry place. Protect from light. Do not freeze.
Manufacturer	North China Pharmaceutical Company Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	H13020286
Approval Date	August 2, 2024
Shelf Life	24 months

How to use ?

Recommended Dose: For intravenous infusion, adults with normal renal function are usually administered 0.8–1.6 g/day divided into 2–3 doses; for severe MRSA infections or infective endocarditis, the dosage may be adjusted up to 1.6 g/day according to clinical conditions. Pediatric patients are generally administered 16–24 mg/kg/day divided into 2 doses, with dosage adjustments based on age and renal function. For oral treatment of Clostridioides difficile infection, the recommended dose is 0.4 g every 6 hours for 7–14 days.

Time: Administer by slow intravenous infusion only. Each dose should be infused over at least 60 minutes.

Instructions for use: Do not administer by intramuscular injection or rapid intravenous injection. Dose adjustment is required in renal impairment. Therapeutic drug monitoring (TDM) is recommended in high-risk patients.

Interaction: Avoid combination with nephrotoxic or ototoxic drugs such as aminoglycosides, cisplatin, amphotericin B, and loop diuretics when possible. Monitor renal function and hearing if combination therapy is necessary.

Side effects: Common adverse reactions include infusion reactions, rash, nausea, injection-site irritation, and elevated liver enzymes. Serious adverse reactions include nephrotoxicity, ototoxicity, red man syndrome, severe allergic reactions, and blood abnormalities.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is WanXun® used for?

It is used for severe Gram-positive bacterial infections, especially infections caused by MRSA, MRSE, and other resistant Gram-positive pathogens.

Is WanXun® (Norvancomycin Hydrochloride for Injection) effective against Gram-negative bacteria?

No. Norvancomycin has no clinically relevant activity against Gram-negative bacteria.

How is WanXun® (Norvancomycin Hydrochloride for Injection) administered?

It is administered by slow intravenous infusion under medical supervision. Oral administration is only used for intestinal C. difficile infection.

Why is therapeutic drug monitoring needed?

Monitoring helps maintain effective drug levels while reducing the risk of kidney and hearing toxicity, especially in elderly patients or those with renal impairment.